Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:31PM ET
5.26
Dollar change
-0.49
Percentage change
-8.53
%
Index- P/E- EPS (ttm)-0.93 Insider Own8.07% Shs Outstand44.68M Perf Week2.33%
Market Cap235.01M Forward P/E- EPS next Y-1.05 Insider Trans0.84% Shs Float41.07M Perf Month189.00%
Income-41.47M PEG- EPS next Q-0.25 Inst Own12.13% Short Float6.85% Perf Quarter246.04%
Sales0.49M P/S479.61 EPS this Y-4.78% Inst Trans-10.89% Short Ratio1.72 Perf Half Y228.74%
Book/sh1.56 P/B3.37 EPS next Y-8.26% ROA-41.90% Short Interest2.81M Perf Year246.04%
Cash/sh1.67 P/C3.14 EPS next 5Y- ROE-47.07% 52W Range0.94 - 6.42 Perf YTD255.39%
Dividend Est.- P/FCF- EPS past 5Y35.42% ROI-58.24% 52W High-18.07% Beta1.95
Dividend TTM- Quick Ratio7.41 Sales past 5Y9.26% Gross Margin18.44% 52W Low459.55% ATR (14)0.61
Dividend Ex-Date- Current Ratio7.41 EPS Y/Y TTM-4.47% Oper. Margin-9305.74% RSI (14)63.00 Volatility13.85% 19.01%
Employees32 Debt/Eq0.03 Sales Y/Y TTM26.42% Profit Margin-8496.93% Recom1.00 Target Price10.50
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q-7.34% Payout- Rel Volume0.44 Prev Close5.75
Sales Surprise212.00% EPS Surprise21.38% Sales Q/Q21.87% EarningsFeb 29 AMC Avg Volume1.63M Price5.26
SMA2015.92% SMA5087.65% SMA200191.76% Trades Volume561,066 Change-8.53%
Date Action Analyst Rating Change Price Target Change
Jan-05-22Initiated William Blair Outperform
Dec-08-21Initiated Robert W. Baird Outperform $19
Aug-09-21Resumed Maxim Group Buy $30 → $20
Oct-22-20Initiated H.C. Wainwright Buy $27
Oct-08-20Initiated Piper Sandler Overweight $25
Mar-21-24 07:55AM
Mar-14-24 08:50AM
08:08AM
Mar-06-24 04:05PM
12:00PM
10:12AM Loading…
Mar-01-24 10:12AM
Feb-29-24 07:40PM
04:07PM
04:06PM
04:05PM
Feb-26-24 08:00AM
Feb-22-24 08:00AM
Jan-17-24 10:30AM
Nov-20-23 04:05PM
Nov-02-23 04:05PM
04:05PM Loading…
Oct-26-23 04:05PM
Oct-23-23 08:45AM
Oct-11-23 09:35AM
Sep-26-23 04:05PM
Sep-05-23 08:00AM
Aug-09-23 04:05PM
Aug-07-23 04:05PM
Jul-24-23 05:09PM
Jun-20-23 05:22PM
Jun-05-23 08:00AM
May-04-23 04:10PM
Mar-28-23 08:00AM
Mar-06-23 08:15AM
Mar-04-23 07:11AM
Mar-02-23 04:10PM
08:15AM Loading…
Feb-27-23 08:15AM
Feb-02-23 08:00AM
Jan-10-23 08:00AM
Nov-21-22 10:52AM
Nov-08-22 08:15AM
Nov-03-22 04:10PM
Sep-12-22 04:05PM
Sep-10-22 07:30AM
Sep-08-22 08:15AM
Sep-06-22 08:00AM
Aug-29-22 08:00AM
Aug-04-22 04:10PM
Jul-05-22 08:30AM
Jul-02-22 09:10AM
May-17-22 08:30AM
May-09-22 08:02AM
May-05-22 04:10PM
Apr-12-22 04:00PM
Apr-08-22 01:05PM
01:05PM
Mar-22-22 09:05AM
Mar-17-22 06:32AM
Mar-08-22 04:45PM
Mar-01-22 08:30AM
Feb-24-22 04:10PM
Feb-17-22 03:02PM
Jan-31-22 06:22PM
Jan-20-22 03:44PM
01:46PM
Jan-18-22 05:00PM
Jan-13-22 09:17AM
Jan-11-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-10-21 08:30AM
Dec-08-21 09:38AM
Dec-03-21 08:30AM
Nov-18-21 07:00AM
Nov-14-21 07:18AM
Nov-09-21 08:30AM
Nov-04-21 04:15PM
Oct-28-21 03:06PM
Sep-30-21 08:36PM
Sep-15-21 06:37AM
Sep-08-21 04:00PM
Sep-07-21 08:30AM
Aug-25-21 08:15AM
Aug-06-21 04:15AM
Aug-05-21 04:15PM
Aug-03-21 03:01PM
Jul-12-21 08:00AM
Jul-06-21 08:30AM
Jun-28-21 08:30AM
Jun-10-21 12:30PM
Jun-08-21 08:30AM
May-24-21 08:35AM
02:09AM
May-20-21 08:30AM
May-06-21 04:10PM
Apr-23-21 11:39AM
Apr-12-21 06:00AM
Apr-10-21 08:30AM
08:30AM
Apr-08-21 08:30AM
Mar-25-21 01:41AM
Mar-11-21 08:30AM
Mar-10-21 04:30PM
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PACE GARY WDirectorDec 19 '23Buy1.3730,00041,100697,761Dec 19 06:39 PM
Last Close
Mar 28 02:27PM ET
2.50
Dollar change
0.00
Percentage change
0.00
%
HEPA Hepion Pharmaceuticals Inc daily Stock Chart
Index- P/E- EPS (ttm)-12.51 Insider Own1.42% Shs Outstand4.34M Perf Week7.76%
Market Cap10.85M Forward P/E- EPS next Y- Insider Trans8.83% Shs Float4.28M Perf Month-9.42%
Income-47.82M PEG- EPS next Q- Inst Own17.21% Short Float1.32% Perf Quarter-30.36%
Sales0.00M P/S- EPS this Y- Inst Trans-46.96% Short Ratio0.71 Perf Half Y-45.65%
Book/sh3.77 P/B0.66 EPS next Y- ROA-94.36% Short Interest0.06M Perf Year-81.62%
Cash/sh4.44 P/C0.56 EPS next 5Y- ROE-118.48% 52W Range1.49 - 20.66 Perf YTD-22.84%
Dividend Est.- P/FCF- EPS past 5Y64.56% ROI-293.56% 52W High-87.90% Beta1.54
Dividend TTM- Quick Ratio3.32 Sales past 5Y0.00% Gross Margin- 52W Low67.79% ATR (14)0.29
Dividend Ex-Date- Current Ratio3.32 EPS Y/Y TTM-5.70% Oper. Margin0.00% RSI (14)55.58 Volatility10.76% 13.79%
Employees25 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price22.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q-22.30% Payout- Rel Volume0.31 Prev Close2.50
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume79.19K Price2.50
SMA204.89% SMA5014.95% SMA200-50.17% Trades Volume19,501 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jul-20-20Resumed ROTH Capital Buy $14
Mar-06-24 08:30AM
Feb-16-24 08:00AM
Jan-03-24 05:15PM
Dec-07-23 08:00AM
Nov-28-23 04:15PM
04:05PM Loading…
Nov-13-23 04:05PM
Nov-10-23 08:50AM
Oct-25-23 08:30AM
Sep-29-23 08:00AM
Sep-21-23 04:05PM
08:00AM
Sep-19-23 09:00AM
Sep-18-23 11:01AM
Sep-14-23 08:45AM
Sep-06-23 04:30PM
04:45PM Loading…
Jun-15-23 04:45PM
08:22AM
May-24-23 04:45PM
May-22-23 07:00AM
May-19-23 04:05PM
May-10-23 11:15AM
Apr-17-23 04:15PM
Mar-30-23 08:45AM
Mar-16-23 04:10PM
Mar-02-23 04:15PM
09:15AM
Feb-09-23 04:15PM
Jan-18-23 09:15AM
Jan-10-23 04:15PM
Jan-09-23 08:00AM
04:15PM Loading…
Jan-05-23 04:15PM
Dec-05-22 04:30PM
09:00AM
Nov-07-22 08:00AM
Nov-04-22 08:30AM
Nov-02-22 08:00AM
Oct-26-22 08:00AM
Oct-20-22 04:30PM
Oct-19-22 08:00AM
Sep-26-22 05:00PM
Sep-14-22 08:00AM
Sep-12-22 08:00AM
Sep-08-22 08:00AM
Aug-31-22 08:00AM
Jul-22-22 04:15PM
Jul-04-22 10:23AM
Jun-28-22 08:30AM
Jun-24-22 04:15PM
Jun-20-22 08:00AM
Jun-15-22 08:00AM
Jun-14-22 08:00AM
May-31-22 04:30PM
May-27-22 08:54AM
08:00AM
May-03-22 08:00AM
Mar-07-22 08:00AM
Feb-15-22 08:00AM
Feb-14-22 08:00AM
Jan-26-22 08:00AM
Jan-12-22 08:00AM
Jan-06-22 04:15PM
Jan-05-22 04:30PM
08:30AM
Dec-21-21 08:00AM
Nov-30-21 08:00AM
Nov-16-21 08:45AM
Nov-10-21 08:00AM
07:55AM
Nov-04-21 08:00AM
Nov-02-21 08:00AM
Oct-07-21 08:00AM
Sep-29-21 09:00AM
Sep-13-21 08:00AM
Sep-10-21 04:05PM
Aug-15-21 05:50AM
Jul-23-21 04:40PM
Jul-13-21 08:00AM
Jun-25-21 04:30PM
Jun-09-21 07:45AM
May-16-21 05:10AM
May-06-21 07:45AM
Apr-29-21 09:50AM
Mar-23-21 07:15AM
Mar-22-21 04:30PM
Mar-11-21 07:30AM
Feb-18-21 04:30PM
Feb-16-21 06:45AM
Feb-12-21 04:45PM
Feb-10-21 07:30AM
Feb-09-21 04:30PM
Feb-05-21 02:00AM
Jan-29-21 03:07PM
Jan-05-21 08:00AM
Dec-29-20 04:15PM
07:30AM
Dec-22-20 07:30AM
Dec-10-20 08:55AM
Dec-02-20 07:30AM
Nov-30-20 05:30PM
Nov-24-20 07:20PM
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wijngaard PeterDirectorNov 27 '23Buy3.052,5007,6259,501Nov 28 06:55 AM
Wijngaard PeterDirectorNov 24 '23Buy3.092,5007,7257,001Nov 28 06:55 AM
Wijngaard PeterDirectorSep 19 '23Buy5.641,0005,6404,501Sep 20 11:27 AM
Foster Robert TCEO and DirectorSep 18 '23Buy5.601,6008,96050,470Sep 19 09:01 AM
Wijngaard PeterDirectorSep 15 '23Buy5.602,00011,2013,501Sep 20 11:27 AM
Foster Robert TCEO,CSO and DirectorSep 15 '23Buy5.401,6008,64048,870Sep 18 08:00 AM